Related Experiment Video
Updated: Jun 8, 2025
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.7K
Evidence That Regulatory And Market Forces Are Driving Adoption Of Biosimilars
Janice Jhang1, Troyen A Brennan2
1Janice Jhang (janicejhang@g.harvard.edu), Harvard University, Cambridge, Massachusetts.
Health Affairs (Project Hope)
|November 4, 2024
Summary
The US biosimilar market, initially disappointing, is now flourishing, offering opportunities to reduce biologic drug costs. Policy interventions can further accelerate biosimilar adoption and affordability.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Biotechnology
Background:
- The US biosimilar market has underperformed since its inception, raising concerns about its future.
- Biosimilars offer a critical pathway to manage rising biologic drug expenditures and enhance medication accessibility.
- Understanding market dynamics across different drug classes and financial stakeholders is crucial.
Purpose of the Study:
- To evaluate the evolution and current state of the US biosimilar market.
- To identify factors contributing to market performance and future viability.
- To examine policy and market dynamics through a case study.
Main Methods:
- Review of medication class distinctions and financial stakeholder involvement.
- Analysis of recent evidence on the post-approval biosimilar marketplace.
- Case study analysis of adalimumab biosimilar entry and market impact.
Main Results:
- Despite early challenges, the US biosimilar market is showing signs of maturation and growth.
- The introduction of biosimilars for adalimumab illustrates evolving market and policy trends.
- Evidence suggests a flourishing post-approval biosimilar landscape.
Conclusions:
- The US biosimilar market is evolving positively, with increasing signs of success.
- Policy makers can leverage regulatory and payment strategies to further boost biosimilar uptake.
- Accelerating biosimilar adoption is key to controlling healthcare costs and improving patient access to essential medicines.
Related Concept Videos
01:03Drug Control Governance: Regulatory Bodies and Their Impact
144
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
144
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
01:16Bioequivalence: Overview
926
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
926
01:19Pharmacovigilance
776
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
776
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
01:17Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K